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Summary An IgGI monoclonal antibody (MAb Cx-99) has been established which recognises a surface
antigen on epithelial cells, but not on fibroblastic or hematopoietic cells. Immunohistochemical studies showed
that this antigen was present in all 37 squamous cell carcinomas (SCC) including 33 cervical SCC, and 30 of
the 32 adenocarcinomas examined; most of the 33 cervical SCC were stained extensively. It was also detected
in the culture medium of cervical cancer cell lines. In the normal cervix, this antigen was restricted to the
undifferentiated basal cells. This observation suggests that the widespread expression of the antigen was
triggered by oncogenesis. The MAb Cx-99 recognised an epitope on an asialyted glycoprotein which has an
apparent molecular weight of 37 kilodaltons (kD) (and 2 minor proteins at 18 and 27 kD) and an isoelectric
point (pI) of 5.3. It may have potential for studies on differentiation and oncogenesis and for diagnostic
applications.
Squamous cell carcinoma (SCC) of the uterine cervix is a
malignancy that is highly prevalent worldwide. In Taiwan,
where this study was conducted, cervical SCC has a very high
prevalence and is the leading cause of death of all female
cancers (Chen, 1986). Conventional examinations still have
limitations with regards to sensitivity and specificity in diag-
nosis and to monitoring of the disease. Thus, an additional
tumour marker would be helpful.
Tumour markers used for studying cervical carcinoma in-
clude carcinoembryonic antigen (CEA), TA-4, epithelial
membrane antigen (EMA), antigens recognised by MAb
17.13 or MAbs CE400-413, and cytokeratins (Rutanen et al.,
1978; Kato et al., 1979; Bamford et al., 1983; Randen et al.,
1987; Koprowska et al., 1986; Bobrow et al., 1986). There
has been limited success in the early diagnosis and monitor-
ing of the disease. Most of these markers have considerable
crossreactivity with normal human tissues, usually in a spor-
adic way, therefore limiting their functional roles. We present
here the derivation and characterisation of a monoclonal
antibody which recognises a surface antigen of human cer-
vical carcinoma. It seems to have potential for diagnostic
application. This antibody was produced through immunisa-
tion with tissue fragments of cervical carcinomas and
through systemic screenings using a variety of human cell
lines and tissues.
Materials and methods
Cell lines and tissues
The mouse myeloma P3-NSI-Ag4-1 (NS-1) was maintained
in RPMI-1640 medium containing 20 mM HEPES and 10%
foetal calf serum (FCS) (Flow, North Ryde, Australia). Of
the five cervical carcinoma cell lines studied, SIHA, ME180,
HeLa, and Caski were obtained from the ATCC (American
Tissue Culture Collection), and CC7T was obtained from Dr
T.M. Chang, Veterans General Hospital (VGH), Taipei (Ko
et al., 1980). TL, a trophoblast-like cell line, was obtained
from Dr C.K. Ho, VGH (Ho et al., 1987). LS174T, a colon
carcinoma cell line, was obtained from Dr B.W. Tom,
University of Texas Medical School, Houston. The three
hepatoma cell lines, HuH 7, Ha4T/V(GH and HA22T/VGH,
were a gift from Dr C.P. Hu, VGH (Hu et al., 1986; Chang
et al., 1983). Other cell lines were purchased from the ATCC:
a foreskin fibroblast cell line, FS-4; an embryonal kidney
line, HEK; a glioma line, G9T; three leukaemia cell lines,
U937, HL-60 and KG-1; an oesophageal carcinoma, CE48T;
and six colon adenocarcinoma cell lines, CCL 220.1, SW 620,
CCL220, SW480, CCL224 and SW 1083. The HeLa cells
and SIHA cells were cultured in minimal essential medium
(MEM) with 10% (FCS); ME180 was cultured in McCoy's
5A medium; and all other cell lines were maintained in
DMEM containing 10% FCS.
Normal and malignant human tissues were collected post-
operatively. One aliquot was stored frozen, and another ali-
quot was fixed in 10% buffered-formalin and then embedded
in paraffin. Some specimens were fixed with 4% paraformal-
dehyde and 0.5% glutaraldehyde before embedding.
Preparation ofmembrane-enrichedfractions ofhuman cervical
carcinoma
Carcinoma tissues were collected from four patients with
cervical SCC after radical hysterectomy. After excision of the
necrotic areas, 12 gm of fresh tissues were washed and minc-
ed finely, placed into 1:3 (w/v) deionised distilled water, and
homogenised three times with a blender at 4°C for 10 s each
time. The homogenate was then sonicated three times, each
for 20 s (Ultrasonic 2000 Artek System Co., NY). The tissue
sediment was discarded, and the unsedimented material was
centrifuged at 100,000 g for I h. The precipitate (0.5 ml) was
diluted with phosphate-buffered saline (PBS) and stored in 10
aliquots (I ml each) for immunisation.
Tissue extraction
Finely minced human SCC tissues were homogenised inter-
mittently for 2 min in three volumes (w/v) of a solution
containing 0.01 M Tris-HCI, pH 7.8, 0.14 M NaCl, 1% NP-
40, 0.1 mM MgCl2, 0.1 mM phenylmethysulfonyl fluoride
(Sigma, MO, USA), 0.25% Triton X-100 (Merck, Darmstadt,
Germany) and 10% glycerol.
The homogenate was sonicated then stirred at 4°C for 2 h.
The sonicated solution was centrifuged at 100,000 g for I h,
and the supernatant was stored in 1 ml aliquots at - 20°C.
The protein content was determined spectrophotometrically
(Lowry et al., 1951), and each aliquot was adjusted to con-
tain 2.5 mg of protein per ml.
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Production ofmonoclonal antibody
Six-week-old Balb/c mice were immunised subcutaneously
with 1 ml of an emulsion containing equal amounts of the
membrane-enriched fraction and complete Freund's adju-
vant, and then they were boosted intraperitoneally with a
mixture of membrane-enriched fraction and incomplete
Freund's adjuvant given every 2 weeks for five injections; the
final booster was given intravenously.
Three days after the last injection, lymphocytes were taken
to make the monoclonal antibody by the cell fusion tech-
nique as previously reported (Tsai et al., 1985). In brief,
spleen cells (1.6 x 108) were fused with 2 x 107 mouse mye-
loma cells (NS-1) in 1 ml of 50% polyethylene glycol 4000
(Merk Darmstadt, Germany), and then cultured in HAT-
containing RPMI-1640 medium in 96-well microplates
(Nunc, Denmark). Fourteen days after the fusion, super-
natants were tested by ELISA against two cervical cancer cell
lines, CC7T and SIHA, and the fibroblast cell line FS-4.
Positive cultures were further selected by the immunohisto-
chemical staining on tissue sections of cervical SCC and of
normal cervix. Hybridomas whose antibodies reacted much
stronger against cancerous tissues than normal cervical
epithelium were selected. Subcloning was performed by the
limiting dilution method. In addition, ascitic fluid containing
the antibodies was prepared by intraperitoneal injection of
5 x 106 hybridoma cells into Balb/c mice which had been
previously primed with 0.5 ml pristane (Sigma, MO, USA) 2
weeks ago. The antibody was purified by precipitation twice
with 45% saturated ammonium sulfate followed by a DEAE-
ion exchange column chromatography, and it was stored at
- 70°C until used.
Enzyme-linked immunosorbent assay (ELISA) and
immunofluorescence (IF)
In ELISA, 5 x 104 cells were placed in each well of the
96-well plate which was precoated with 100 p1 of 10 ,gml-'
poly-L-lysine, and cultured at 37°C for 48 h. Nonspecific
binding sites were blocked with 1% bovine serum albumin
(BSA) in 10 mM phosphate buffered saline (PBS) and 0.02%
sodium azide. Then, 50f1d aliquots of culture supernatant
were added and incubated for 30 min at 37°C. Unbound
immunoglobulin was removed by washing with PBS, pH 7.2,
containing 0.05% Tween-20. Diluted peroxidase-conjugated
rabbit anti-mouse IgG (DAKO, Glostrup, Denmark) was
added for 30 min at 37°C, followed by 50 pLI of 2,2'-azino-bis
(3-ethylbenzthiazoline-6-sulfonic acid) (ABTS, pH 4.8) with
0.0002% H202 for 30 min at room temperature. The absor-
bance at 415 nm was read using a Multiscan spectrophoto-
meter (Flow Lab, Scotland). The NS-1 culture supernatant or
0.1% Balb/c mouse sera was used as a negative control.
The reactivities toward leukaemia cell lines and isolated
blood cells were determined by the IF method after fixing the
cells onto microscopic slides, as described by others (John-
stone & Thorpe, 1987). Mononuclear leukocytes were prepar-
ed by density gradient centrifugation using Ficoll-Hypaque
(English et al., 1974).
Immunohistochemistry
The histochemical staining was performed according to Hsu's
method (Hsu & Raine, 1981). Briefly, sections of tissues were
reacted with culture supernatants for 30 min at room temp-
erature after removal of endogenous peroxidase by prein-
cubation for 30 min at room temperature with methanol
containing 0.3% H202, followed by diluted biotin-labelled
horse anti-mouse IgG (1:400 Vector Lab, Burlingame, CA).
The avidin-biotin-peroxidase complex (ABC, Vector Lab)
was then applied, followed by development in 3-amino-9-
ethyl carbazol (AEC)-3% H202 solution. The NS-1 culture
supernatant was used as the negative control.
Immunoglobulin isotype
Aliquots of 0.1 ml of goat anti-mouse IgG (50 sgml-' in
PBS) were coated onto polyvinyl 96-well microtiter plates
and incubated sequentially with each of the following for 1 h:
0.1 ml of culture supernatant; 50 p11 of rabbit antiserum
specific for mouse immunoglobulins (Ig) A, M, GI, G2a,
G2b or G3; 50p1 of diluted peroxidase-labelled goat anti-
rabbit antibody; and 100 tl of substrate ABTS (monoAb-ID
EIA kit, Zymed, USA).
SDS-PAGE, isoelectrofocusing (IEF) and immunoblotting
Tissue extracts were subjected to 13.5% SDS-polyacrylamide
slab gel electrophoresis under non-reducing or reducing (2-
mercaptoethanol) conditions as described by Laemmli (1970),
using 30-40 jig protein in each lane. Then the protein was
transferred electrophorectically onto nitrocellulose paper
according to the method of Towbin et al. (1979) (Hoefer
Scientific Instruments, USA). The membrane strips were
blocked overnight with 1% BSA and incubated with undilut-
ed hybridoma supernatants for 1 h. The strips were incubated
for 30 min with diluted alkaline-phosphatase-conjugated
rabbit anti-mouse IgG antibody (Sigma, MO), followed by
60 min incubation with substrates containing 25 mg of fast
red (Sigma, MO) and 10 mg of alpha-nathyl-phosphate
(Sigma, MO) in 50 ml of 50 mM Tris-HCl, pH 8.2. All incu-
bations were performed at room temperature.
The IEF was performed by polyacrylamide IEF gel electro-
phoresis at 100 V for 15 min, 200 V for 15 min, and 450 V
for 1 h (Mini IEF Cell, Bio-Rad Mode 111). The separated
proteins were electrotransferred onto the nitrocellulose paper
in 0.7% acetate in distilled H20, pH 2.8, at 1 A for 40 min
(Hoefer Instrument), then used in the reactions described
above.
Other biochemical characterisations
The CC7T cells, 5 x 105, were treated with the following
reagents in different concentrations: trypsin (0.01- 1%),
periodic acid (0.05-5%) (Sigma, MO) and neuraminidase
(0.01-1.0 U ml 1) (Behringwerke AG, Marburg). After incu-
bation at 37°C for 30 min, these cells were washed three
times, put in poly-L-lysine coated 96-well plate, centrifuged
at 2,000 r.p.m. for 10 min, and fixed with 0.5% glutaral-
dehyde in PBS at room temperature for 15 min. Then the
ELISA assay was performed as described above, and immuno-
histochemical studies were performed on tissue sections
pretreated with these reagents.
Specificity
Purified antigens of CEA (DAKO, Glostrup, Denmark) were
used to coat a 96-well plate at 0.05jig per well respectively.
MAb Cx-99 were added and the reactivities were determined
by the ELISA assay described above. In excluding cross-
reactivity with the TA-4 (SCC) Antigen, 50 ng of the stan-
dard TA-4 (SCC) Antigen from the diagnostic kit (Dainabot,
Tokyo) was mixed with MAb Cx-99 in four diluted concen-
trations, then quantitations of the standard TA-4 (SCC)
Antigen from these mixtures was performed by radio-
immunoassay according to the diagnostic kit.
Detection ofthe MAb-eliciting antigen in culture mediumfrom
cervical cancer cell lines
First, a competitive inhibition ELISA test was performed.
The wells coated with SIHA cells were reacted with culture
supernatant containing MAb Cx-99 as the control. To test
for antigen shedding by the various cancer cell lines, 50pl of
spent medium from these cell lines in conventional culture
containing 10% FCS were reacted with 50p1 of the culture
supernatant containing MAb Cx-99 at 37°C for 2 h, and the
mixtures were subjected to reaction with coated SIHA cells
by ELISA assay to determine whether the MAb was stillMONOCLONAL ANTIBODY AGAINST CERVICAL CANCER 203
Table I Immunohistochemical reactivity of MAb Cx-99 with various neoplasms
Number
Specific Reactivity Positive
Neoplasm neoplasm Total 0 + ++ +++ ++++ (%)
SCC 37 100
Cervix 33 1
CIN III 11 1 1 9
Invasive 22 2 3 16
Vagina 1 1
Lung 1 1
Tongue 1 1
Neck 1 1
Adenocarcinoma 32 94
Cervix 4 4 100
Endometrium 5 2 3 100
Ovary 9 1 4 0 1 3 89
Stomach 3 1 1 1
Colon 7 2 1 1 3 100
Breast 1 1
Kidney 2 1 1
Bile duct 1 1
Hepatoma 3 2
Uterine sarcoma 2 2
Synovial sarcoma 1 1
Melanoma 1 1
Uterine myoma 5 5
Reactivity was expressed on an arbitrary degree of staining: 0, <5% staining of the
cancerous area; +, 5-30%; + +, 30-50%; + + +, 50-70%; + + + +, 70- 100%.
alive. Second, a confirmation experiment by ELISA assay on
serum-free medium was performed. The SIHA cells were
cultured in serum-free medium containing growth factors for
4-6 days. Then 50 LI of this medium containing 75,ug ml-'
of protein were coated in each well, incubated at 4°C over-
night, reacted with the purified ascitic MAb Cx-99 in various
dilutions from 10-2 (38.4,tgml-' of protein) to 10-6, and
assayed by ELISA.
Results
Production ofMAb Cx-99
After fusing, 78 of 556 wells containing hybridoma cells
showed a 4-fold or higher absorbance above background
when reacted with the cervical carcinoma cell lines CC7T and
SIHA. The hybridomas whose supernatants also showed a
positive reaction to the foreskin fibroblast cell line FS-4 were
excluded. After secondary screening by immunoperoxidase
staining on tissues of cervical carcinomas, nine wells that
showed stronger staining with the cervical carcinomas than
with normal tissues were isolated for subcloning. The MAb
Cx-99, which showed the strongest activity and seemed
stable, was finally selected for further characterisation.
Determination ofantibody specificity by immunohistochemistry
Using the immunoperoxidase method, all 22 cases of invasive
squamous cell carcinoma and all 11 cases of cervical intra-
epithelial neoplasia III (CIN III) of the uterine cervix were
stained with MAb Cx-99 (Table I). Nineteen of the 22 inva-
sive cervical SCC had more than half of their cancerous areas
stained, and no differences in staining were found between
keratinised and nonkeratinised types. Islands of SCC were
clearly stained in primary cerivcal lesions as well as in meta-
static lymph nodes (Figure la-c). Of the 11 cases of CIN III,
nine had staining on the entire epithelium of anaplastic cells
(Figure Id). The reactivity to MAb Cx-99 in all four cases of
CIN I and two of the four cases of CIN II was confined to
the dysplastic areas, which were located at the lower to
middle layers of epithelia, but in two cases of CIN II, the
staining pattern was similar to that of CIN III (Data not
shown).
All stromal tissues including fibroblasts, blood cells, blood
vessels were not stained. In contrast to the widespread re-
activity in the cervical carcinoma, normal cervix was stained
in only some discrete areas, including the basal cells of the
ectocervical epithelium and the subcolumnar cells of the
endocervical glands at the transformation zone (Figure le
and f).
All SCC other than cervical carcinoma and most of the
adenocarcinomas, including ovarian carcinoma, stained
immunohistochemically with MAb Cx-99, whereas most of
the other types of tumours did not (Table I). In one case of
synovial sarcoma, reactivity was present only in the epithelial
components. Some normal epithelial tissues including endo-
metrial glands, fallopian tube, colon, the ductal epithelia of
the liver and kidney, sweat glands, trophoblasts of normal
placentas and some foetal tissues were also stained (Table II).
In contrast to the extensive reactivity of ovarian carcinomas,
normal ovarian tissues were not reactive.
The patterns and intensities of staining in frozen sections
or in glutaraldehyde-paraformaldehyde-fixed tissues were
similar to those of formalin-fixed sections.
Reactivity ofMAb Cx-99 with cell lines and isolated
leukocytes
The MAb Cx-99 reacted with all five cervical cancer cell lines
as determined by ELISA on coated cells in 96-well plates
(Table III). Similar results could also be observed in one of
three hepatoma cell lines, two of six colon cancer cell lines,
and the trophoblast-like TL cell line but not in any of the
stromal cell lines or three different leukaemia cell lines (Table
III).
Characteristics ofthe antigen recognised by MAb Cx-99
The isotype of MAb Cx-99 is IgGI. Analysis of the antigen
that reacts with MAb Cx-99 by SDS-PAGE under non-
reducing or reducing (2-ME) conditions revealed a similar
pattern, i.e., a band corresponding to a relative molecular
mass of 37 kD, and fainter bands of 27 kD and 18 kD
(Figure 2a). By IEF and blotting with MAb Cx-99, a single
band at pI 5.3 was obtained (Figure 2b). Treatment of cancer
tissues or cells with periodic acid or trypsin destroyed their
reactivity with MAb Cx-99, but treatment with neuramini-
dase did not (Figure 3). Identical results were found in tissues
stained after treating with these reagents. Therefore, the
epitope of MAb Cx-99 seems to be a glycoprotein without
sialic acid residue. Further immunoassay tests showed that204 C.C. YUAN et al.
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Figure 1 Immunoperoxidase staining of invasive cervical SCC with MAb Cx-99. a, large-cell non-keratinised type; b, keratinised
type; c, pelvic lymph node showing a metastasis; d, CIN III; e, nornal ectocervical epithelium; f, normal endocervix. Bars: a to
e=8.6 p; f=5.61 .
MAb Cx-99 did not crossreact with CEA and TA-4 (SCC)
Antigen.
Detection ofthe antigen in culture medium ofcell lines
Competitive inhibition tests showed that culture medium
from certain cell lines, including CC7T, ME180 and SIHA,
decreased the reactivity between MAb Cx-99 and the SIHA
cells, whereas others, such as HEK, Caski, HeLa and Huh-7,
did not (Figure 4a). Further studies utilising SIHA super-
natant generated in serum-free medium as the coated antigen
in the ELISA assay also demonstrated the presence of the
shedding antigen in the culture supernatant (Figure 4b).
Discussion
We report the establishment of a MAb to cervical carcinoma,
designated MAb Cx-99. The eliciting antigen is present only
in epithelial cells, but not in fibroblastic or hematopoietic
cells, and it is found immunohistologically in 100% of the 37
SCCs and 94% of the 32 adenocarcinomas examined; most
b
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Table II ReactivityofMAbCx-99with normalhuman tissuesbyABC
staining
Positivel Positivel
Tissue total no. Tissue total no.
Cervix 8/10a Colon 2/3
Ovary 0/7 Heart 0/3
Endometrium 6/8 Testis 0/3
Fallopian tube 5/6 Lymph node 0/5
Vagina 4/6a Placenta 5/8
Spleen 0/3 Foetal kidney
Pancreas - duct 3/3 - tubule 1/1
- others 0/3 - glomerulus 0/1
Kidney - tubule 4/4 Foetal heart 0/2
- glomerulus 0/4 Foetal lung
Liver - hepatocyte 0/4 - bronchiole 2/2
- duct 3/4 - others 0/2
Adrenal gland 0/3 Foetal testis 0/1
Skin - epidermis 0/4 Foetal spleen 0/2
- sweat gland 3/3 Foetal liver
Peritoneum 0/5 - hepatocyte 1/3
Lung 0/3 - duct 2/3
aOnly the basal cells were positive.
Table III Reactivity ratio of MAb Cx-99 with human cell lines by
ELISA
Reactivity Reactivity
index index
Cell line (RI) Cell line (RI)
Cervical carcinoma Esophageal carcinoma
CC7T 4.1 CE48T/VGH 1.4
ME-180 3.5 Hepatoma
SIHA 5.2 HuH-7 3.3
Caski 3.2 HA22T/VGH 1.3
HeLa 3.0 HA47T/VGH 1.1
Colon carcinoma
CCL 220 1.2 Foreskin fibroblast FS-4 1.1
SW 620 4.0 Embryonal kidney HEK 1.6
CCL 224 3.7 Melanoma H2484 0.9
SW 480 2.4 Trophoblast-like TL 4.5
LS 174T 0.7 Glioma G9T 1.3
SW 1083 0.8
Reactivity index is the absorbance ratio of the reactivity of MAb
Cx-99 to that of the NS-1 supernatant in ELISA. The assay was
considered positive when RI >3.0; negative when RI <1.5 and
borderline when 3.0 > RI > 1.5.
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of these tissues were stained extensively. In contrast to the
diffused expression of this antigen in all of the 22 invasive
cervical SCC, it was present only in the undifferentiated basal
cells of the cervix and reserve cells of the transformation.
These cell types are rapidly replicating in normal differen-
tiation and are the source of the cells that undergo malignant
transformation (Dallenbach-Hellweg & Poulsen, 1990). In
CIN III, MAb Cx-99 stained the entire epithelial layer, which
was composed of anaplastic cells. These findings identify a
phenotypic similarity between cervical cancer cells and im-
mature cells. We suggest that cervical carcinoma cells retain
the capability of expressing the antigen reactive with MAb
Cx-99, which is normally found in the basal cells, during
oncogenesis. This antigen may be valuable in identifying
undifferentiated epithelial cells and for studies on
differentiation and oncogenesis.
The MAb Cx-99 may be a valuable tool for the diagnosis
of cervical carcinoma. Small foci of cancer cells could be
detected in primary lesions and in metastatic lymph nodes;
hence, MAb Cx-99 can reveal micrometastases or micro-
invasion. The ability of the epitope with which it reacts to
withstand formalin and various other fixatives makes MAb
Cx-99 quite useful in surgical pathology. The positive
Figure 2 Analysis of relative molecular mass and PI. a, Western
blotting using MAb Cx-99 after SDS-PAGE separation of the
tumour extract. Lane A: reactivity with MAb Cx-99 after SDS-
PAGE separation under reducing conditions (2-ME). Lane B:
reactivity under nonreducing conditions. Lanes C & D: controls
in which MAb Cx-99 was replaced by PBS and NS-I super-
natant, respectively. b, Western blotting using MAb Cx-99 after
IEF separation of the tumour extract. Lane S: standard pH
markers (Bio-Rad). Lanes A & B: reactivity with MAb Cx-99
(duplicate tests). Lane C: control in which MAb Cx-99 was
replaced by NS-1 supernatant.
immunostaining in cancer tissues provides a favourable basis
for its application in vivo, in tumour localisation (Tsai et al.,
1988). The reactivity pattern of Cx-99 may also open the
possibility of using this antibody on smears for the early
detection of cervical carcinoma, because reactivity was found
from CIN lesions to invasive carcinomas. Finally, since the
antigen recognised by MAb Cx-99 can be detected in the
culture medium, it may be present in the serum of patients
with cervical cancer or with adenocarcinomas.
. T... -- W-: m.206 C.C. YUAN et al.
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Figure 3 Analysis of epitope reactive with MAb Cx-99 by treat-
ment with various biochemical reagents. Positive control (PC):
reagents were replaced by PBS. Negative control (NC): MAb
Cx-99 was replaced by PBS. All tests were performed duplicate.
The epitope that reacts with MAb Cx-99 is carried on an
asialyted glycoprotein with a relative molecular mass of
18-37 kD and a pI of 5.3. It apparently does not crossreact
with CEA and TA-4 (SCC) Antigen. Also, its physiochemical
and antigenic properties are distinct from those of other
reported epithelial cell-associated antigens. Tissue poly-
peptide antigen (TPA) is a 45 kD complex related to cyto-
keratins number 8, 18 and 19 that is also located in the basal
cells of the normal squamous epithelium; however it has
rarely been found in keratinised cervical SCC and is absence
in the normal endocervical columnar cells (Stegner et al.,
1986). MAb 17.13 reacts with a basal cell antigen, but is not
present in adenocarcinomas (Randen et al., 1987). MAb
17-lA is a 37 kD glycoprotein, but unlike MAb Cx-99, the
epitope that it recognises contains sialic acid residues. Also,
the SDS-PAGE banding pattern of the molecule reactive
with MAb 17-lA was changed under reducing condition
(Gottlinger et al., 1986); therefore, its epitope is structurally
different from that recognised by MAb Cx-99 which was not
changed under reducing conditions in SDS-PAGE. MAb
MOv18 and 19 have a relative molecular weight similar to
the antigen that reacts with MAb Cx-99, but they are differ-
ent in immunohistochemistry (Miotti et al., 1987). The other
antigens of SCC include human milk fat globulin (HMFG 1
and 2), epithelial membrane antigen (EMA), VM-2, MAbs
CE 400-413, cytokeratins of low molecular weight such as
CAM 5.2, and antigens reactive with antibodies SQM1 and
Ca 1. However, all of these antigens are different from the
antigen recognised by MAb Cx-99 in molecular weight,
biochemical characteristics and tissue distribution (Fray et
al., 1984; Bamford et al., 1983; Mortenn et al., 1985; Kop-
rowska et al., 1986; Bobrow et al., 1986; Boeheim et al.,
1985; Ashall et al., 1982).
In summary, we have established a MAb that recognises
an antigen present only in epithelial cells. Based on its
pattern of reactivity, we suggest that MAb Cx-99 may be
a
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Figure 4 Detection of the antigen reactive with MAb Cx-99 in
the culture medium of various cell lines, a, A competitive inhibi-
tion ELISA test, 1 X and 10 x dilutions of the culture medium
were used. A: SIHA culture medium was replaced by PBS (posi-
tive control). B: MAb Cx-99 was replaced by PBS (negative
control). b, ELISA assay of SIHA supernatant generated in
serum-free medium. This antigen preparation was used to coat
the wells, and is reacted with MAb Cx-99 (0). Replacing the
antibody with PBS eliminated the reactivity with SIHA super-
natant-coated wells (absorbance <0.09). The titration curve of
MAb Cx-99 with SIHA cells is also shown (*).
useful for the rapid diagnosis of cervical carcinomas and the
detection of micrometastases or microinvasion. Since it is
shed by cell lines in culture, it may be present in the sera of
patients with SCC or with adenocarcinomas.
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